… MEK inhibitor (MEKi) monotherapy provides limited clinical benefits but may serve as a
foundation for combination therapies. Here, we showed that combining a type II RAF inhibitor (…

… , MEK inhibitors have also been evaluated in combination … which used a MEK inhibitor,
sometimes in combination with a … we discuss the potential of combining inhibitors which target two …

… the combination of BRAF inhibitor and MEK inhibitor gives an increased cardiovascular toxicity
compared to the monotherapy with BRAF inhibitor, … with BRAF inhibitor and MEK inhibitor, …

… to single‐agent tyrosine kinase inhibitors or to treat cancers with … combination binimetinib
(MEK inhibitor) and buparlisib (PI3K inhibitor) in patients harboring alterations in the RAS/RAF …

… As an additional control, we treated VMM18 melanoma cells with U0126, a MEK inhibitor,
which blocked serum-stimulated phosphorylation of both p70S6K and 4EBP1 (Figure 4, lane 6)…

… The concomitant inhibition of the ERK and PI3K pathway was … of different MEK inhibitors
combined with chemotherapy or … in combination with GSK2118436 (another MEK inhibitor), …

… inhibited in their growth following the combined administration of lapatinib and trametinib. To
determine the extent of MEK inhibition … , trametinib, or the combination therapy for 24 hours …

… Resistance to BRAF or MEK inhibitors is associated with the … combination of a RAF or MEK
inhibitor with an AKT or mTOR … with a MEK inhibitor upon progression on a BRAF inhibitor in …

… ), combining inhibitors of RAF and MEK may … of MEK inhibitors is an acneiform rash resulting
from inhibition of ERK activity in normal skin (22). In contrast, treatment with RAF inhibitors …

… of MEK in progressive melanomas and summarize latest results of clinical studies with …
MEK inhibitors and/or combined approaches with other kinase inhibitors such as BRAF inhibitors …